May 6, 2020 / 5:11 AM / 20 days ago

BRIEF-Relief Therapeutics: Drug Aviptadil Enters FDA Trial To Treat Covid-19-Induced Acute Respiratory Distress

May 6 (Reuters) - RELIEF THERAPEUTICS HOLDING SA:

* DRUG AVIPTADIL ENTERS FDA TRIAL AT NYU LANGONE HEALTH, NEW YORK, TO TREAT COVID-19-INDUCED ACUTE RESPIRATORY DISTRESS Source text> bit.ly/2zhxZiY Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below